Natixis Seres Therapeutics, Inc. Transaction History
Natixis
- $19.1 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding MCRB
# of Institutions
100Shares Held
62.7MCall Options Held
36.9KPut Options Held
476K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$16.6 Million1.17% of portfolio
-
Black Rock Inc. New York, NY6.83MShares$4.91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.73MShares$4.85 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT5.43MShares$3.91 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA2.13MShares$1.54 Million0.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $89.3M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...